Zydus Lifesciences received USFDA approval for its Diroximel Fumarate capsules for multiple sclerosis, while concluding a USFDA inspection at its oncology plant in Ahmedabad with two observations.
Zydus Lifesciences received USFDA approval for its Diroximel Fumarate capsules for multiple sclerosis, while concluding a USFDA inspection at its oncology plant in Ahmedabad with two observations.